The CHS / Pfizer Care Until Cure Research Program

The CHS / Pfizer Care Until Cure Research Program was established in the year 2000 in collaboration with Wyeth Canada, now Pfizer. Pfizer Canada strives every day to help Canadians live healthy, balanced lives. They do that by discovering and developing innovative medicines. As a company, they're dedicated to building healthier communities and empowering Canadians to make healthier choices every day. At Pfizer Canada, they believe that to be truly healthy, it takes more than medication.

This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder.

For the 2018-2019 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas.

 

Agency Name: 
Canadian Hemophilia Society
Contact Name: 
Penny D'Agnone
Grant Amount: 
For the CHS / Pfizer Care Until Cure Research Program, individual grants valued at $75,000 per year will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. Grant funding will begin on April 1, 2018.
Grant Location: 
External
External Deadline: 
Wednesday, November 15, 2017
Grant Type: 
Research
Grant Area: 
Health
Grant Eligibility: 
Faculty